CA3227153A1 - Treatment of his hyporesponders - Google Patents

Treatment of his hyporesponders Download PDF

Info

Publication number
CA3227153A1
CA3227153A1 CA3227153A CA3227153A CA3227153A1 CA 3227153 A1 CA3227153 A1 CA 3227153A1 CA 3227153 A CA3227153 A CA 3227153A CA 3227153 A CA3227153 A CA 3227153A CA 3227153 A1 CA3227153 A1 CA 3227153A1
Authority
CA
Canada
Prior art keywords
obicetrapib
therapy
ldl
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227153A
Other languages
English (en)
French (fr)
Inventor
Johannes Jacob Pieter KASTELEIN
Marc DITMARSCH
Michael Harvey Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewAmsterdam Pharma NV
Original Assignee
NewAmsterdam Pharma NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NewAmsterdam Pharma NV filed Critical NewAmsterdam Pharma NV
Publication of CA3227153A1 publication Critical patent/CA3227153A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
CA3227153A 2021-07-26 2022-07-25 Treatment of his hyporesponders Pending CA3227153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21187721 2021-07-26
EP21187721.2 2021-07-26
PCT/EP2022/070780 WO2023006657A1 (en) 2021-07-26 2022-07-25 Treatment of his hyporesponders

Publications (1)

Publication Number Publication Date
CA3227153A1 true CA3227153A1 (en) 2023-02-02

Family

ID=77358089

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227153A Pending CA3227153A1 (en) 2021-07-26 2022-07-25 Treatment of his hyporesponders

Country Status (17)

Country Link
US (1) US20230041138A1 (cg-RX-API-DMAC7.html)
EP (2) EP4376832B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527023A (cg-RX-API-DMAC7.html)
KR (1) KR20240040767A (cg-RX-API-DMAC7.html)
CN (1) CN117940125A (cg-RX-API-DMAC7.html)
AU (1) AU2022320869A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227153A1 (cg-RX-API-DMAC7.html)
DK (1) DK4376832T3 (cg-RX-API-DMAC7.html)
ES (1) ES3071242T3 (cg-RX-API-DMAC7.html)
FI (1) FI4376832T3 (cg-RX-API-DMAC7.html)
IL (1) IL310115A (cg-RX-API-DMAC7.html)
LT (1) LT4376832T (cg-RX-API-DMAC7.html)
MX (1) MX2024001170A (cg-RX-API-DMAC7.html)
PL (1) PL4376832T3 (cg-RX-API-DMAC7.html)
PT (1) PT4376832T (cg-RX-API-DMAC7.html)
TW (1) TWI922719B (cg-RX-API-DMAC7.html)
WO (1) WO2023006657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2025146415A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
EP4746866A1 (en) * 2024-09-17 2026-05-27 NewAmsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026146129A1 (en) * 2025-01-02 2026-07-09 Newamsterdam Pharma B.V. Magnesium salts of obicetrapib
WO2026146132A1 (en) * 2025-01-02 2026-07-09 Newamsterdam Pharma B.V. Salts of obicetrapib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
KR20150028233A (ko) 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-3 지방산의 조성물
CN107108558B (zh) 2014-08-12 2019-11-19 狄智玛制药私人有限公司 制备用于制备四氢喹啉衍生物的合成中间体的方法
MX376135B (es) * 2014-08-28 2025-03-04 Newamsterdam Pharma B V Composicion farmaceutica y combinacion terapeutica que comprende un inhibidor de la proteina de transferencia de colesteril ester e inhibidores de hmg coa reductasa

Also Published As

Publication number Publication date
JP2024527023A (ja) 2024-07-19
AU2022320869A1 (en) 2024-02-01
TW202310842A (zh) 2023-03-16
CN117940125A (zh) 2024-04-26
US20230041138A1 (en) 2023-02-09
DK4376832T3 (da) 2026-06-15
WO2023006657A1 (en) 2023-02-02
PT4376832T (pt) 2026-06-11
EP4789665A1 (en) 2026-08-12
PL4376832T3 (pl) 2026-08-10
TWI922719B (zh) 2026-04-21
IL310115A (en) 2024-03-01
LT4376832T (lt) 2026-07-10
KR20240040767A (ko) 2024-03-28
ES3071242T3 (en) 2026-06-22
MX2024001170A (es) 2024-05-14
FI4376832T3 (fi) 2026-06-10
EP4376832A1 (en) 2024-06-05
EP4376832B1 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
EP4376832B1 (en) Obicetrapib for use in treating of cardiovascular disease (cvd) in his hyporesponders
US9849104B2 (en) Treatment of NASH with gemcabene
JP6419927B2 (ja) 対象の高感度(hs−crp)のレベルを低下させる組成物および方法
JP6196225B2 (ja) 糖尿病新規発症低減用組成物
RU2765218C2 (ru) Фиксированные комбинации и составы, содержащие етс1002 и один или более статинов, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
KR20080024511A (ko) 심혈관 이벤트 발병 예방용 조성물
JP2007277267A (ja) (e)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3r,5s)−3,5−ジヒドロキシヘプツ−6−エン酸と、p450アイソザイム3a4の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ
Farnier et al. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy
TW201906605A (zh) 用於治療共核蛋白病的斯他汀組合物及方法
US9974767B2 (en) Statins in the treatment of muscular dystrophies and myopathies
WO2025059594A1 (en) METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
TWI741379B (zh) 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合
KR20020086749A (ko) 베타 블록커 및 콜레스테롤 저하제의 신규한 조합물
ES2811302T3 (es) Uso de inhibidores de la PDE4 para la profilaxis y/o la terapia de la dislipoproteinemia y trastornos relacionados
JP6207560B2 (ja) 膵炎を治療するためのゲムカベンおよび誘導体
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
ES2274892T3 (es) Uso de un betabloqueante para el tratamiento de aterosclerosis.
EP3791874A1 (en) Medication useful for cardiovascular diseases
WO2014034871A1 (ja) 脂質異常症の予防又は治療薬
WO2026062050A1 (en) Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
Ashcheulova et al. Dislipidemia: definition, diagnostics and treatment
HK1256960A1 (en) Treatment of mixed dyslipidemia

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250708

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260717

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260717

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260722